“showed an 81% relative decrease in BCRL with BIS as compared to circumference measures. The fact that the analysis is both statistically and clinically significant really stresses the need for widespread prospective BCRL surveillance with BIS.”
“The meta-analysis demonstrates the effectiveness of L-Dex in reducing BCRL when compared to tape measure and will form the basis of what we believe will be a strong submission to the NCCN in coming months. This Level 1 evidence is a key step in making L-Dex the standard of care for all patients at risk of developing breast cancer- related lymphoedema,”
“showed an 81% relative decrease in BCRL with BIS as compared to...
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $161.8M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 8.0¢ | $104.8K | 1.309M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 166577 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.1¢ |
Change
0.000 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.1¢ | 8.0¢ | 135749 | ||
| Last updated 12.21pm 03/05/2024 ? | |||||
| IPD (ASX) Chart |